1. An abnormal digital rectal exam result or elevated serum PSA measurement could indicate prostate cancer. The exact cut-off level of what is considered to be a normal PSA value has not yet been determined, but values around < 2.5–3ng/ml are often used for younger men. ( C ) 2. The diagnosis of prostate cancer [...]
Primary Treatment Options for Prostate Cancer
Deferred Treatment The rationale for deferred treatment is that prostate cancer often progresses slowly, and is diagnosed in older men in whom there is a high incidence of co-morbidity and related high competitive mortality. Watchful waiting can be considered as an option for treating patients with localised prostate cancer in whom life expectancy is limited [...]
Prostate Cancer Survey highlights need for patient information tools post diagnosis
A recent survey by Astellas Pharma Co. Ltd researched patients’ access to information, treatment options provided upon diagnosis, treatment decision support and general patient care management. Entitled “Silent Voices”, the survey took place in France, Italy, Spain, Poland, Germany and Ireland and researched 50 prostate cancer patients in each country. It was undertaken in Ireland [...]
Erectile Dysfunction Treatment Algorithm
First-Line Therapies for Erectile Dysfunction – Oral PDE-5 Inhibitors
The emergence of oral therapy to treat erectile dysfunction (ED) has forever changed the field of male sexual health. While the evaluation and management of ED was primarily in the domain of urologists, now the primary care provider is often the initial evaluator and prescriber of therapy and the urologist typically sees patients where oral [...]
Oral PDE-5 inhibitors characteristics
Sildenafil (Viagra) Onset and duration: • Tmax 30-120 min • Median 60 min • Duration: 4 hrs • Food decreases absorption Dose: • 25-100mg • Initially 50mg Metabolism: • Metabolised by CYP3A4 (major route), 2C9 (minor route) • Concomitant 3A4 inhibitors associated with increased levels. Starting dose: 25mg • Concomitant ritonavir not advised • Severe [...]
PDE-5 inhibitors drug interactions
Sildenafil, vardenafil and tadalafil are primarily metabolised by hepatic enzymes via cytochrome CYP3A4 with some contribution from isoform CYP2C9 for sildenafil and from CYP3A5 and CYP2C for vardenafil. The potential exists for adverse drug interactions with drugs which inhibit or induce CYP3A4 and anti-hypertensive drugs due to their capacity to diminish blood pressure. CYP3A4 inhibitors [...]
Degarelix shows a significantly greater probability of PSA recurrence-free survival compared with leuprolide in prostate cancer patients
Results from a phase III pivotal study sub-analyses recently published in European Urology show that prostate cancer patients who received Firmagon (degarelix) have a statistically significant greater probability of prostate-specific-antigen (PSA) recurrence-free survival compared with those taking leuprolide (p=0.05) (2). A further sub-analysis from the same study, published in the British Journal of Urology International [...]
Zoledronic Acid Prevents Fractures in Prostate Cancer With Bone Metastases
Monthly infusions of the bisphosphonate zoledronic acid significantly reduce the risk for bone fractures in men with prostate cancer and malignant bone metastases, according to data presented at the European Association of Urology 25th Annual Congress in April 2010. Claims-based analysis study The study was a claims-based analysis of 4976 men drawn from more than [...]